ALMS (Alumis) Total Receivables: $2.73 Mil (As of Mar. 2026)


ALMS Alumis Inc ALMS
12 GF Score
Price $26.41
! 4 Warning Signs
View Full Analysis

What is Alumis Total Receivables?

Alumis ALMS +5.52% 12 Total Receivables is $2.73 Mil as of Mar. 2026. GuruFocus rates ALMS with a GF Score™ of 12/100. The stock has 4 warning signs investors should review.

Alumis's Total Receivables for the quarter that ended in Mar. 2026 was $2.73 Mil.

Alumis Total Receivables Historical Data

* Premium members only.

The historical data trend for Alumis's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alumis Total Receivables Chart

Alumis Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Total Receivables
0.50 0.72 1.81 2.08

Alumis Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.29 7.86 3.64 2.08 2.73
ALMS
12GF Score
Alumis Inc ALMS
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alumis Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $2.73 Mil mean?
Alumis (ALMS) has a Total Receivables of $2.73 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Alumis and its competitors.
Is Alumis' Total Receivables too high?
Alumis' current Total Receivables is $2.73 Mil. Overall, Alumis has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Alumis' Total Receivables compare to SLNO and ARQT?
Alumis' Total Receivables of $2.73 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Alumis and its competitors. Alumis's current Total Receivables is $2.73 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alumis stock overvalued right now?
Alumis (ALMS) has a current Total Receivables of $2.73 Mil. The current Total Receivables is $2.73 Mil. Alumis' overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Alumis (ALMS), the current Total Receivables is $2.73 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alumis Business Description

Address 280 East Grand Avenue, South San Francisco, CA, USA, 94080
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
12GF Score

Get the complete analysis for ALMS

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.41
Price